PTC Therapeutics Inc (STU:BH3)
€ 36.8 0 (0%) Market Cap: 2.89 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 66/100

PTC Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2021 / 01:00PM GMT
Release Date Price: €34.6 (-2.81%)
Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

Good morning, everyone, and welcome to the 2021 Credit Suisse Healthcare Conference. We're thrilled to have PTC with us this morning. We have CEO, Stuart Peltz, along with Matthew Klein and Kylie O'Keefe.

And with that, I think we could get started with Q&A. (Operator Instructions)

Questions & Answers

Judah C. Frommer;dit Suisse AG
CrÃ;Research Division - Senior Analyst

© -

So Stuart, we thought we could start out with a brief introduction to the business. You have several marketed products, along with a robust pipeline across a number of modalities. So what are the key highlights for someone less familiar with the PTC story?

Stuart W. Peltz
PTC Therapeutics, Inc. - Co-Founder, CEO & Executive Director

Yes. Judah, thanks for having us today. For those who don't know us too well, we're -- PTC is a global biopharmaceutical company that we are focused on discovering,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot